RBC Capital Initiates Coverage On TransDigm Gr with Outperform Rating, Announces Price Target of $700
RBC Capital analyst Ken Herbert initiates coverage on TransDigm Gr (NYSE:TDG) with a Outperform rating and announces Price Target of $700.
Barron’s Latest Picks And Pans: Amazon, Apple, Chevron, Citigroup, Dell And More
This weekend's Barron's cover story features the latest results of the annual Barron's Big Money Poll.
Morgan Stanley Reinstates Overweight on TransDigm Gr, Announces $762 Price Target
Morgan Stanley reinstates TransDigm Gr (NYSE:TDG) with a Overweight and announces $762 price target.
TransDigm Response to Meggitt PLC Announcement
This press release is being issued in response to the announcement from Meggitt PLC regarding TransDigm's approach to Meggitt for a possible acquisition. The below press release was made in accordance with Rule
Truist Securities Maintains Hold on TransDigm Gr, Raises Price Target to $600
Truist Securities analyst Michael Ciarmoli maintains TransDigm Gr (NYSE:TDG) with a Hold and raises the price target from $590 to $600.
Transdigm Q3 Earnings Tops Consensus, Notes Improved Margins, Dodges Outlook
TransDigm Group Inc (NYSE:TDG) reported third-quarter sales growth of 19% year-over-year to $1.218 billion, +15% on an organic basis, versus the…
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck’s Keytruda On Track For More Label Expansions, Eliem Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 9)
TransDigm: Q3 Earnings Insights
Shares of TransDigm Gr (NYSE:TDG) fell 0.5% in pre-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share were up 116.23% year over year to $3.33, which beat the estimate of $2.93.